Let’s Transform Transplant Medicine. Together.
Achieving more through our shared commitment to transplant medicine
See our pipelineLearn more about who we are at Veloxis
Veloxis, an Asahi Kasei company
At Veloxis, our focus is developing new therapies and programs to help transplant healthcare providers and the patients they treat. Now part of a global network, Veloxis is reaching further and growing faster, enabling us to continue being who we are as a company: Agile, Efficient, Responsive. Veloxis is following through on our promise to transform the future of transplant. Let’s transform transplant medicine. Together.
We know what transplant means to patients, and we’re leading innovation to improve their experience
For patients, transplant is a life-changing procedure. But changes come with challenges. At Veloxis, our mission is to see and respond to the challenges along the transplant journey. Our focus is developing new therapies and programs to help transplant healthcare providers and the patients they treat.
As part of a global network, Veloxis is reaching further and growing faster
As an Asahi Kasei company, we are able to expand our presence as a partner in care and innovation in medicine. The support and structured framework we have as part of Asahi Kasei enables us to be who we are as a company: agile, efficient, and responsive.
Meet our leadership
“Veloxis’s Human Resources Department prides itself in providing an exceptional workplace environment for all employees. We strive to maintain a dynamic and innovative workplace that embraces diversity and encourages professional development. Our employees are our top priority!”
Rita Mannella, Executive Director, Human Resources
Keep up with our headlines to see what we’ve been working on
Veloxis Pharmaceuticals Showcases Research at the 2026 American Transplant Congress
Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company part of Asahi Kasei Corporation, which is committed to improving the lives of transplant and other immunocompromised patients, is pleased to announce five poster presentations at the upcoming American Transplant Congress (ATC), taking place June 20-24, 2026 in Boston, Massachusetts, USA.
Pegrizeprument Granted Orphan Drug Designation for Prevention of Organ Rejection in Heart Transplant Patients
Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company part of Asahi Kasei Corporation, announced today that pegrizeprument (also known as VEL-101), a novel investigational maintenance immunosuppressive agent, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the prophylaxis of heart allograft rejection in patients receiving a heart transplant.
Asahi Kasei Completes Acquisition of Aicuris to Advance Its Global Pharmaceutical Strategy
Tokyo—April 20, 2026— Asahi Kasei, a diversified global company, announced the successful completion of its acquisition of Aicuris Anti-infective Cures AG (Aicuris), a German-based biopharmaceutical company. This closing marks a key step in accelerating the company’s efforts to build a global specialty pharmaceutical platform by expanding further into severe infectious diseases.